Oasmia, Pharmasyntez sales and marketing update

Oasmia granted Pharmasyntez exclusive commercialization and distribution rights to Paclical micellular paclitaxel in the Commonwealth of Independent States (CIS) to treat ovarian cancer, lung cancer and second-line breast cancer. Under the deal, Pharmasyntez will finance marketing and sales activities, and Oasmia is responsible for development and manufacturing. Oasmia said the companies will share profit on net sales in the region. The companies could not be reached for details. ...